Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer

ResearchWorks/Manakin Repository

Search ResearchWorks


Advanced Search

Browse

My Account

Statistics

Related Information

Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer

Show simple item record

dc.contributor.author FitzGerald, Liesel M. en_US
dc.contributor.author Agalliu, Ilir en_US
dc.contributor.author Johnson, Karynn en_US
dc.contributor.author Miller, Melinda A. en_US
dc.contributor.author Kwon, Erika M. en_US
dc.contributor.author Hurtado-Coll, Antonio en_US
dc.contributor.author Fazli, Ladan en_US
dc.contributor.author Rajput, Ashish, B. en_US
dc.contributor.author Gleave, Martin E. en_US
dc.contributor.author Cox, Michael E. en_US
dc.contributor.author Ostrander, Elaine A. en_US
dc.contributor.author Stanford, Janet L. en_US
dc.contributor.author Huntsman, David G. en_US
dc.date.accessioned 2010-05-06T20:02:23Z
dc.date.available 2010-05-06T20:02:23Z
dc.date.issued 2008 en_US
dc.identifier.citation FitzGerald L, Agalliu I, Johnson K, et al. Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer. BMC Cancer. 2008;8(1):230. en_US
dc.identifier.other 10.1186/1471-2407-8-230 en_US
dc.identifier.uri http://www.biomedcentral.com/1471-2407/8/230 en_US
dc.identifier.uri http://hdl.handle.net/1773/15811
dc.description.abstract Background: The presence of the TMPRSS2-ERG fusion gene in prostate tumors has recently been associated with an aggressive phenotype, as well as recurrence and death from prostate cancer. These associations suggest the hypothesis that the gene fusion may be used as a prognostic indicator for prostate cancer. Methods: In this study, fluorescent in situ hybridization (FISH) assays were used to assess TMPRSS2-ERG fusion status in a group of 214 prostate cancer cases from two population-based studies. The FISH assays were designed to detect both fusion type (deletion vs. translocation) and the number of fusion copies (single vs. multiple). Genotyping of four ERG and one TMPRSS2 SNPs using germline DNA was also performed in a sample of the cases (n = 127). Results: Of the 214 tumors scored for the TMPRSS2-ERG fusion, 64.5% were negative and 35.5% were positive for the fusion. Cases with the TMPRSS2-ERG fusion did not exhibit reduced prostate cancer survival (HR = 0.92, 95% CI = 0.22-3.93), nor was there a significant difference in causespecific survival when stratifying by translocation or deletion (HR = 0.84, 95% CI = 0.23-3.12) or by the number of retained fusion copies (HR = 1.22, 95% CI = .45-3.34). However, evidence for reduced prostate cancer-specific survival was apparent in those cases whose tumor had multiple copies of the fusion. The variant T allele of the TMPRSS2 SNP, rs12329760, was positively associated with TMPRSS2-ERG fusion by translocation (p = 0.05) and with multiple copies of the gene fusion (p = 0.03). Conclusion: If replicated, the results presented here may provide insight into the mechanism by which the TMPRSS2-ERG gene fusion arises and also contribute to diagnostic evaluations for determining the subset of men who will go on to develop metastatic prostate cancer. en_US
dc.description.sponsorship This work was supported by NIH grants RO1 CA56678, RO1 CA114524, and P50 CA97186; additional support was provided by the Fred Hutchinson Cancer Research Center and the Intramural Program of the National Human Genome Research Institute. en_US
dc.language.iso en_US en_US
dc.title Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer en_US
dc.type Article en_US


Files in this item

Files Size Format View
1471-2407-8-230.pdf 662.0Kb PDF View/Open

This item appears in the following Collection(s)

Show simple item record